AID Autoimmun Diagnostika GmbH

AID Autoimmun Diagnostika GmbH is a biotechnology and manufacturing company founded in 1988 in Germany. The company specializes in producing and selling diagnostic products, imaging devices, and software programs related to immunology and infectious diseases. AID's flagship product, the AID EliSpot Reader System, is one of the most widely used systems of its kind globally. The company continuously focuses on developing complete automatable solutions, particularly in the fields of microbiology, virology, and cell biology. Their newest developments include the AID BacSpot Robotic System, capable of analyzing up to 200 agar plates per hour, and the AID EliSpot Robotic System, the first high-throughput analyzing system for EliSpot assays worldwide. AID also offers a comprehensive range of test systems for research and diagnostic labs, with a specific emphasis on automatable test systems for streamlining documentation and archiving of results. With no public information available regarding their last investment and the investors involved, AID Autoimmun Diagnostika GmbH presents an intriguing opportunity for potential venture capital interest. The company's track record of innovation and the potential for growth in the biotechnology and manufacturing sectors make it worth monitoring for potential investment opportunities. More information can be found on their website: [AID Autoimmun Diagnostika GmbH](https://www.aid-diagnostika.com/topmenu/impressum-datenschutz/)